Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ramucirumab plus paclitaxel second-line therapy in elderly gastric cancer
jRCT1031200158Phase 2Recruiting
- Start
- May 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and paclitaxel in gastric adenocarcinoma and gastric cancer (GC). Primary endpoint: Safety. Started May 2016; status: recruiting.
02
Drugs
ramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on jRCT1031200158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031200158.